tropisetron Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Tropisetron is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.   Wikipedia

Chemistry

  • SMILES: CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c3c[nH]c4ccccc34
  • InChIKey: ZNRGQMMCGHDTEI-ITGUQSILSA-N
  • Mol. Mass: 284.36
  • ALogP: 2.95
  • ChEMBL Molecule:
    tropisetron  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$3.8610
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1h-indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo- | (3 alpha-tropanyl)-1h-indole-3-carboxylic acid ester | ics 205-930 | ics-205930 | ics-205-930 | indole-3-carboxylic acid tropine ester | navoban | novartis brand of tropisetron hydrochloride | tropisetron | tropisetron hcl | tropisetron hydrochloride

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Nausea

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Chronic Disease (Phase 2)

Colorectal Neoplasms (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Emergence Delirium (Phase 4)

Liver Neoplasms (Phase 2)

Nausea (Phase 4)

Neoplasms (Phase 2)

Pain (Phase 4)

Pain, Postoperative (Phase 4)

Postoperative Cognitive Complications (Phase 4)

Postoperative Complications (Phase 4)

Schizophrenia (Phase 3)

Smoking Cessation (Phase 3)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue